Searching for a Novartis weight loss injection? Here's what the evidence says

Why Novartis doesn't make the weight loss jab people are asking about

Novartis is one of the world's largest pharmaceutical companies, and it does have medicines in development across metabolic conditions. But as of summer 2026, no Novartis injection is licensed by the MHRA for weight management in UK adults. The confusion likely stems from widespread press coverage of GLP-1 medicines as a category, articles sometimes describe the broader pharmaceutical landscape without making clear which company makes which product.

The two injectable treatments licensed in the UK for obesity are made by entirely different manufacturers. Tirzepatide, sold as Mounjaro, is an Eli Lilly product. Semaglutide, sold as Wegovy, is made by Novo Nordisk, and if you want to understand how the Novo weight loss injection works and what it involves, that page covers the detail clearly. Both are prescription-only medicines dispensed through GPhC-registered pharmacies. If someone recommended a "Novartis" weight loss pen specifically, it is worth verifying the source, unlicensed products and counterfeit pens are a documented problem the MHRA has acted on repeatedly. The regulator keeps a public register you can search at the GPhC pharmacy register to confirm any pharmacy offering these treatments is legitimate.

For a full picture of what injectable options exist in the UK, the licensed weight loss injections overview is a good starting point.

What the clinical evidence behind the licensed injections actually shows

Both licensed injectable medicines have substantial trial programmes behind them. The SURMOUNT-1 study (randomising 2,539 adults with obesity over 72 weeks) reported average body-weight reduction of around 20–21% at the 15 mg tirzepatide dose, according to data published in the New England Journal of Medicine. That figure comes from a tightly controlled trial alongside a reduced-calorie diet and increased physical activity; real-world results vary, and no individual outcome can be guaranteed.

For semaglutide 2.4 mg, the STEP 1 trial (68 weeks, also published in the NEJM) reported approximately 15% average weight reduction. A higher 7.2 mg semaglutide dose was approved by the MHRA in January 2026, with trial data suggesting around 20.7% average weight loss, narrowing the gap between the two medicines considerably. NICE has also assessed both treatments formally: tirzepatide under TA1026 and semaglutide under TA875.

These figures reflect what happened in clinical populations. A prescriber weighs that evidence alongside your specific health picture (BMI, comorbidities, other medicines, medical history) before deciding whether either treatment is appropriate for you.

Eligibility thresholds for the two licensed injectable options

Both medicines share broadly similar eligibility criteria under their UK licences. Adults with a BMI of 30 or above qualify, as do those with a BMI from 27 upwards if they have at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone never decides approval: the prescriber considers the whole picture.

On the NHS, access follows a phased rollout tied to stricter thresholds and comorbidity counts, criteria that many people won't meet yet, or won't meet without a long wait. Private treatment through a regulated pharmacy is the alternative for those who are eligible under the licensed criteria but not the NHS scheme, or who simply don't want to wait, and people searching for weight loss injections in Bournemouth can find out what local private access looks like on that page. The cost of weight loss injections in the UK page sets out what private pricing typically looks like, including what a legitimate price should include.

Neither medicine is licensed for use during pregnancy, breastfeeding, or when trying to conceive. They are not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma or certain pancreatic conditions should discuss this with a prescriber before considering either treatment.

Practical realities: storage, routine, and what ongoing treatment involves

Both Mounjaro and Wegovy are once-weekly subcutaneous injections administered via pre-filled pens. The pen lives in the fridge (2 to 8°C) until you need it, so slotting it into the routine of a weekly injection on the same day each week tends to make adherence straightforward. Always check the Patient Information Leaflet for the exact room-temperature window if you're away from home; the SmPC published on the electronic Medicines Compendium carries the precise storage guidance.

Injection sites rotate between the abdomen, thigh, and upper arm. Correct injection technique matters, and a prescriber or pharmacist can walk you through it. Good aftercare (clinical support when side effects arise or dose adjustments are needed) is as important as the medicine itself. The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, and indigestion tend to be most noticeable in the first weeks after starting or after a dose increase, and they often settle. Severe or persistent stomach pain that radiates to the back needs prompt medical attention, as the MHRA flagged acute pancreatitis as a known (though infrequent) risk in its January 2026 Drug Safety Update for GLP-1 medicines.

If you'd like to explore whether either of the licensed injectable treatments is appropriate for you, our clinical team at nume's prescribing team reviews consultations the same day. You can also read more about non-injection weight loss options if an oral route appeals, or browse the full treatment overview before deciding. When you're ready, speak to our prescribers through a free consultation, no referral, no waiting list, just a clinical assessment to see whether treatment is right for you.